KU-55933 (ATM Kinase Inhibitor)

For research use only. Not for use in humans.

製品コードS1092

KU-55933 (ATM Kinase Inhibitor)化学構造

分子量(MW):395.49

KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR. KU‑55933 (ATM Kinase Inhibitor) inhibits the activation of autophagy‑initiating kinase ULK1 and results in a significant decrease of autophagy.

サイズ 価格(税別) 在庫  
10mM (1mL in DMSO) JPY 20500 あり
JPY 13600 あり
JPY 21900 あり
JPY 63400 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(179)

製品安全説明書

ATM/ATR阻害剤の選択性比較

生物活性

製品説明 KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR. KU‑55933 (ATM Kinase Inhibitor) inhibits the activation of autophagy‑initiating kinase ULK1 and results in a significant decrease of autophagy.
ターゲット
ATM [1]
(Cell-free assay)
12.9 nM
体外試験

KU-55933 inhibits DNA-PK and PI3K with IC50 of 2.5 μM and 16.6 μM, respectively. Besides, KU-55933 also prevents the activity of mTOR with IC50 of 9.3 μM. KU-55933 is active at the cellular level in ablating a well-characterized ATM-dependent phosphorylation event. KU-55933 has a dose-dependent effect in inhibiting this ATM-dependent phosphorylation event with IC50 of 300 nM. KU-58050 does not prevent the ATM-dependent phosphorylation of p53 serine 15 until a dose of 30 μM. Addition of KU-55933 has no appreciable effects on UV-induced phosphorylation of H2AX on serine 139, NBS1 on serine 343, CHK1 on serine 345, and SMC1 on serine 966. In stark contrast to the UV responses, KU-55933 ablates the ionizing radiation-induced phosphorylation of these ATM substrates. KU-55933 sensitizes HeLa cells to a range of ionizing radiation doses. [1] KU-55933 inhibits the phosphorylation of Akt induced by growth factors in cancer cells. KU-55933 suppresses the proliferation of cancer cells. Furthermore, suppression of ATM by KU-55933 improves survival, probably via prevention of downstream activation of TAp63α. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-145 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvPbIh3UUN3ME2zMlI4OzV{IN88US=> Mo\HV2FPT0WU
HuO-3N1 Mn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVqzS|FPUUN3ME20MlE4OTR{IN88US=> NIO3UlRUSU6JRWK=
LAMA-84 NIDqXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1z0fGlEPTB;ND61PFQ3PSEQvF2= M1q2SnNCVkeHUh?=
CAL-72 M4LqSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\Gb3pKSzVyPUWuOFgxQDRizszN MVjTRW5ITVJ?
LoVo NV64[Yh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTZwOUOyN|kh|ryP NFTkcpZUSU6JRWK=
HH MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\tflhvUUN3ME24MlI4PjdzIN88US=> MUTTRW5ITVJ?
SK-MEL-3 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRThwMki1O|Uh|ryP MojrV2FPT0WU
KM12 NGfG[ppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTlwMkGxOFIh|ryP NUPHUWJSW0GQR1XS
NCI-H1437 NWPScGZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXL4RnFiUUN3ME25MlgxQTdizszN M{\Qc3NCVkeHUh?=
NCI-H1838 NWTuXnNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTFzLkG4OlUh|ryP NH7nTWlUSU6JRWK=
J-RT3-T3-5 NUHSOFFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXNXFNKSzVyPUGxMlI1OTdizszN NVjtVHU3W0GQR1XS
GOTO NHPueplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTFzLk[5PVYh|ryP Ml7EV2FPT0WU
LB2241-RCC MlHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fTTWlEPTB;MUGuO|E5PiEQvF2= NHXD[VdUSU6JRWK=
ES7 Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zhUWlEPTB;MUGuO|g5KM7:TR?= MlLQV2FPT0WU
KP-N-YS MmPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fDO2lEPTB;MUKuOlM2PCEQvF2= M2HC[XNCVkeHUh?=
CAL-12T NXnwSHk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzUN|hvUUN3ME2xN{43OTdizszN MVHTRW5ITVJ?
COLO-684 NI\T[VZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDDUFVvUUN3ME2xOE4yPTZ7IN88US=> MkLUV2FPT0WU
DOK NXXLUWhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnDPWtKSzVyPUG1MlM{OjlizszN NHrud4tUSU6JRWK=
Hs-578-T NVXWc2VsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTYSlF5UUN3ME2xOU41OTh{IN88US=> NIfrXlFUSU6JRWK=
D-423MG MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVG3eo1mUUN3ME2xOU42OjN4IN88US=> M37ZZXNCVkeHUh?=
DBTRG-05MG MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrHTWM2OD1zNT62NVEyKM7:TR?= NYnjfGNnW0GQR1XS
VM-CUB-1 MoTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPLVYtKSzVyPUG1Mlk5PDlizszN MXHTRW5ITVJ?
KG-1 MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmP5TWM2OD1zNj6wPVk3KM7:TR?= NV;ENllvW0GQR1XS
8305C MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmixTWM2OD1zNj6xPFg6KM7:TR?= NIfVN5FUSU6JRWK=
HuH-7 MkjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPWTGNKSzVyPUG2MlI3PzRizszN M2Oxd3NCVkeHUh?=
LXF-289 MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zmeWlEPTB;MU[uNlc1PyEQvF2= MVPTRW5ITVJ?
NCI-H1793 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTF4LkS3NVIh|ryP NVvFXWl7W0GQR1XS
ChaGo-K-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVH3T3ZTUUN3ME2xOk43PTZ6IN88US=> MlHUV2FPT0WU
GCIY MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH72[XdKSzVyPUG2Mlc6ODVizszN M33oRXNCVkeHUh?=
SK-MEL-28 M4TCe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTF5LkC0O|Uh|ryP MUnTRW5ITVJ?
NCI-SNU-1 MmT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTF5LkGyOlkh|ryP MlfYV2FPT0WU
CTB-1 NITRcZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWWze5lPUUN3ME2xO{4zOjV7IN88US=> MWXTRW5ITVJ?
NCI-H82 M4jRZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rYbGlEPTB;MUeuOFU4OyEQvF2= NVu5fYNwW0GQR1XS
HCC2998 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTF5Lk[3N|Mh|ryP MojOV2FPT0WU
NCI-H2030 Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFX3bWdKSzVyPUG4MlE6QTdizszN NEG0cI1USU6JRWK=
HuP-T3 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NESxb|JKSzVyPUG4MlU5QDhizszN NFT2bVJUSU6JRWK=
697 M4X1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HKTGlEPTB;MUmuNFIxOSEQvF2= NETzcJVUSU6JRWK=
MLMA MmfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLpWmNKSzVyPUG5MlA2PTdizszN NX\Bd3RZW0GQR1XS
HCC70 M2PQ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7uN3NKSzVyPUG5MlQ5QSEQvF2= NWrqeW5[W0GQR1XS
A704 Mnq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fVeWlEPTB;MUmuPFMxPSEQvF2= MlO5V2FPT0WU
D-283MED NVrsVZFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2OwfGlEPTB;MkCuOVM{QSEQvF2= NEDBN|RUSU6JRWK=
U031 M{XZ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkS3TWM2OD1{MT6xOFg6KM7:TR?= MVzTRW5ITVJ?
HSC-3 NGHIW4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHrTWM2OD1{MT6xPFM2KM7:TR?= MmHTV2FPT0WU
JVM-3 NX;adHdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTJ{LkWwOkDPxE1? MWrTRW5ITVJ?
Mewo NUDrdpE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFK2bIRKSzVyPUKyMlUxPzNizszN MXHTRW5ITVJ?
YH-13 M36zWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYOzPZI2UUN3ME2yNk42OTJ|IN88US=> NF;wRXdUSU6JRWK=
LB1047-RCC MlL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Plc2lEPTB;MkKuOVg4QSEQvF2= M3zGSXNCVkeHUh?=
HCC2157 MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjtXG9KSzVyPUKyMlgxPTRizszN NUDRWVFkW0GQR1XS
SNU-449 M3PY[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHm5VldKSzVyPUKyMlg4PDhizszN M1fFenNCVkeHUh?=
Ramos-2G6-4C10 M4i3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHSXol2UUN3ME2yNk46PiEQvF2= M1LZT3NCVkeHUh?=
CHL-1 M1u2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHMboZKSzVyPUKzMlczQTJizszN MXnTRW5ITVJ?
SK-MEL-30 NGfJV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2T2N2lEPTB;MkSuOFY3OiEQvF2= MkHuV2FPT0WU
PANC-08-13 Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXRV4RuUUN3ME2yOU4xQTN6IN88US=> NHn2PW1USU6JRWK=
QIMR-WIL MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLTWJFKSzVyPUK1MlE5PThizszN NXu2cXpnW0GQR1XS
BFTC-905 NX\NNldqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;sU3JKSzVyPUK1MlU6PDRizszN MnTkV2FPT0WU
GI-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXL3V4FGUUN3ME2yOU44ODV3IN88US=> M322XXNCVkeHUh?=
MDA-MB-415 NWHqPFRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJ4LkWwN|Mh|ryP MkDDV2FPT0WU
GT3TKB MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTJ4LkWzOFIh|ryP NH\UbWVUSU6JRWK=
DEL NIXRfW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTJ4LkizOVYh|ryP MXrTRW5ITVJ?
KOSC-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvNdJJKSzVyPUK2MlkxPzVizszN NFz4SWdUSU6JRWK=
RVH-421 NHPKNolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTJ5LkK5NlEh|ryP NXnIOIkzW0GQR1XS
EW-13 MoezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mny1TWM2OD1{Nz60N|A5KM7:TR?= M2PjNnNCVkeHUh?=
639-V MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmn5TWM2OD1{Nz61NVE6KM7:TR?= MkjOV2FPT0WU
A2780 NFnkVmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXqRWpXUUN3ME2yO{43PDFizszN MWnTRW5ITVJ?
SW982 NHvxUVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXOwTG9IUUN3ME2yO{46ODV{IN88US=> NITCRZJUSU6JRWK=
SW1710 NGPqcotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;hU5ZKSzVyPUK4MlA6QDFizszN NWX0[HY6W0GQR1XS
HCC1569 NFjwVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn34TWM2OD1{OD60PFk4KM7:TR?= M4XjUnNCVkeHUh?=
MV-4-11 MkfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLWOIxUUUN3ME2yPE42PzN3IN88US=> NYfsN3ZPW0GQR1XS
BHT-101 NFKyc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVS4Z4ZVUUN3ME2yPE43PTd{IN88US=> M4nX[XNCVkeHUh?=
Ca9-22 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTJ6LkexOEDPxE1? NV\1dFdWW0GQR1XS
HAL-01 NWHvXFhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojuTWM2OD1{OD63OlE2KM7:TR?= NVnXdWdwW0GQR1XS
D-263MG NY[x[VZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXKTWM2OD1{OT6zOFQh|ryP MWrTRW5ITVJ?
NEC8 M{HCXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\0TWlEPTB;MkmuOVU1QCEQvF2= NFy1XGVUSU6JRWK=
EKVX MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PrV2lEPTB;M{GuOVg1PyEQvF2= NWXTN|V4W0GQR1XS
EM-2 NFPF[ZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPYWpJKSzVyPUOxMlY{ODRizszN M{flfnNCVkeHUh?=
MFM-223 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmD6TWM2OD1|MT64NFk5KM7:TR?= NHTYOVBUSU6JRWK=
SK-PN-DW NE[1[|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17FXmlEPTB;M{KuNVQxPiEQvF2= M4CwXHNCVkeHUh?=
HuO9 NGXodXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnnfIFXUUN3ME2zNk42Ojh{IN88US=> M4\ncXNCVkeHUh?=
MHH-PREB-1 NXL6fW06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTN{Lk[yN|Qh|ryP MV7TRW5ITVJ?
OVCAR-4 NUjHbXlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2P0e2lEPTB;M{KuPFM3OyEQvF2= NFvmbJJUSU6JRWK=
NCI-H1648 M3nDOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fHT2lEPTB;M{KuPFY2OSEQvF2= NXP6NWhDW0GQR1XS
MKN1 NE\XTJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTN2LkGxNFEh|ryP MXvTRW5ITVJ?
KYSE-450 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjTTWM2OD1|ND62OFQ1KM7:TR?= NIjlWHpUSU6JRWK=
ES8 NU\NTVdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4S0WmlEPTB;M{SuPFk4PSEQvF2= MVnTRW5ITVJ?
MS-1 NFuybYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTN2Lkm1OVQh|ryP MYLTRW5ITVJ?
HOP-92 NHrNRZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTN3LkmyO|ch|ryP NWfxeIhEW0GQR1XS
SKG-IIIa MnPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTN4LkK1OlEh|ryP NX2zPGpGW0GQR1XS
TE-11 NG\ubJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTN4LkWyOFMh|ryP M1rX[HNCVkeHUh?=
SK-NEP-1 NHvze3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTN5Lk[3OFQh|ryP NHfEeo9USU6JRWK=
DB MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfQT|hKSzVyPUO3MlkyQDVizszN NYLmV3k6W0GQR1XS
IA-LM MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmD2TWM2OD1|OD6wNlM6KM7:TR?= MVzTRW5ITVJ?
COLO-829 M{jqfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{K0c2lEPTB;M{iuOFE2QSEQvF2= M4fX[nNCVkeHUh?=
TGBC11TKB MoHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HybmlEPTB;M{muNVQxQCEQvF2= Ml7rV2FPT0WU
CAL-51 Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVz4eIhXUUN3ME20NE4xPjF{IN88US=> MoCwV2FPT0WU
NCI-H2228 NF34WG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfEUGJKSzVyPUSwMlM3PjJizszN MlnvV2FPT0WU
C32 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3VTWM2OD12MD60NFI1KM7:TR?= MU\TRW5ITVJ?
KU-19-19 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFuzR|JKSzVyPUSwMlc3QDNizszN NEXFV5VUSU6JRWK=
KNS-62 MkKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTRyLkizPFEh|ryP NXr0bFVIW0GQR1XS
FADU MlfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTRzLkK1NFIh|ryP NGe4coNUSU6JRWK=
CAL-33 NEDEXIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXrTWM2OD12Mj62O|Q6KM7:TR?= NUntOIJbW0GQR1XS
CHP-134 MmHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTR{Lki0PVYh|ryP MnX6V2FPT0WU
HDLM-2 NVPZUFN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7yUVlKSzVyPUSyMlkxQDRizszN NXf5S5V2W0GQR1XS
NBsusSR MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrzTWM2OD12Mz6wO|I2KM7:TR?= NWnNNWVGW0GQR1XS
SW954 M1LLOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGn6OlZKSzVyPUSzMlExPTNizszN M1rhTXNCVkeHUh?=
HCC1806 NELMXmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XNOmlEPTB;NEOuOFEyKM7:TR?= NIS2TXFUSU6JRWK=
VMRC-RCZ NVO2bWJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTR|LkS1PFYh|ryP Mmf4V2FPT0WU
A549 NWjEeXhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{m3T2lEPTB;NEOuPVMyKM7:TR?= NGmxd45USU6JRWK=
NKM-1 NEXSV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3wRmhKSzVyPUSzMlk2PThizszN NVHtUnNDW0GQR1XS
DMS-273 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3e4fGlEPTB;NESuO|U3PyEQvF2= M3\Gd3NCVkeHUh?=
TYK-nu MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\YSW1UUUN3ME20OU4yOjN2IN88US=> Mk\6V2FPT0WU
KALS-1 Mm\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vOdWlEPTB;NEWuNVQ3KM7:TR?= MV;TRW5ITVJ?
A101D MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Pm[WlEPTB;NEWuOFQ2PiEQvF2= NIXl[VBUSU6JRWK=
G-361 NXO2XpZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTR4LkKxN|gh|ryP NWLxRpFNW0GQR1XS
KARPAS-299 Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\veIhKSzVyPUS2MlM2OTZizszN MkT3V2FPT0WU
RS4-11 NEnMdJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\QSGJKSzVyPUS2MlU1OiEQvF2= M4rqdHNCVkeHUh?=
HT-1376 NXzSZVE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\vWWlEPTB;NE[uO|QzPiEQvF2= NFHTN5pUSU6JRWK=
SK-N-AS MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnLW2U2UUN3ME20Ok44QDJ{IN88US=> NW\WO|Z[W0GQR1XS
MG-63 NYWxcGNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTR4LkmwN|Yh|ryP MkTuV2FPT0WU
EPLC-272H Mn;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonuTWM2OD12Nj65OVA{KM7:TR?= Mn7zV2FPT0WU
BALL-1 NF7IOXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLMTWM2OD12Nz64N|Ih|ryP NUTDUotUW0GQR1XS
LCLC-97TM1 MnnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzVSHVEUUN3ME20PE4zODJizszN MV;TRW5ITVJ?
HO-1-N-1 NWfvVllUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTR6Lkm2O|Yh|ryP NHjpbWJUSU6JRWK=
MFE-280 NEHhRXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoGyTWM2OD12OT60OlE4KM7:TR?= NWLDdWpIW0GQR1XS
NCI-H526 Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTqTWM2OD12OT64NVY{KM7:TR?= NVyzXpZrW0GQR1XS
D-566MG MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfnblZEUUN3ME20PU46ODl4IN88US=> M4LWb3NCVkeHUh?=
BB30-HNC NYO0V|ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTR7Lkm0PVgh|ryP Mn;wV2FPT0WU
SK-N-DZ MonhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTVyLkC0PFEh|ryP NXPMPXBYW0GQR1XS
HepG2  NEXtfFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXGxNOKh|ryP NXT0VHJnOjRiaB?= NXHRZmhH[myxY3vzJHNENUmLSUOtbY5lfWOnZDDTJJBp[XOnIHHydoV{fA>? NGjVT4gzPTV{N{GyNy=>
HepG2  MUXGeY5kfGmxbjDBd5NigQ>? NXvW[oN7OTEEoN88US=> MXOyOEBp NHrG[WZ{fXCycnXzd4V{KHSqZTDwbI9{eGixconsZZRqd26|IH;mJGFVVSCxbjDT[ZIyQThzLDDDbIsyKG:wIGPldlM1PSxiQ3jrNkBwdiCWaIK2PEwh[W6mIFPkb|Ihd25iVInyNVUhcW6mdXPl[EBjgSCVQz3JTWk{ NFS3[FYzPTV{N{GyNy=>
KATO III  MnjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUCyMlUwPS95LkWg{txO M33QcGROW09? NX\GRYxu\W6qYX7j[ZMhfGinIITvfIlkcXS7IH;mJI9t[XCjcnni NIHz[WozPDh2MUexPC=>
hTCEpi MmnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fVbFExKM7:TR?= M4TaOmROW09? M4HFO5Bz\X[nboTzJJRp\SCleYTvdIF1cGmlIHXm[oVkfCCxZjDIV3YuOQ>? NXjKS21ROjR|N{C4N|U>
MCF10A Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vtc|ExKM7:TR?= MmS5NlQhcA>? NV:zVXh3TE2VTx?= NEX1Oldxd3SnboTpZZRmeyC2aHWgZ5l1d3SxeHnjbZR6KG:oIFfB M3ezUFI1OTVyNUm1
HL-60  MVrGeY5kfGmxbjDBd5NigQ>? NYLIXI1NOTBizszN NEe5XGsxNjViaB?= NUm1R5lJTE2VTx?= MWHy[YR2[2W|IIDoc5NxcG:{eXzheIlwdiCxZjDDbIszyqB? MmLINlM6OzR2MUG=
MCF-7 NUDEfWZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDvfXNJOS1zMEFOwG0> NV;TS2xMOjRiaB?= NUXucJlKTkKV NYnlPW5PcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbh?= Mn;uNlMyQDV|NEe=
HeLa  M2rL[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDYNU0yODEQvF2= M3zsWVI1KGh? NUjUNmFRTkKV M3rESolvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25? MWiyN|E5PTN2Nx?=
SH-SY5Y MWXGeY5kfGmxbjDBd5NigQ>? NHPHZYwyOMLizszNxsA> NWrFV4ZUOjRiaB?= NUfid2NucW6qaXLpeJMh[2yrb4H1bY5wdC2rbnT1Z4VlKHCqb4PwbI9zgWyjdHnvckBw\iCyNUO= NI\TUmozOjZ{N{K5OC=>
IMR-32 NVzVdoJ1TnWwY4Tpc44hSXO|YYm= M4r0PFExyqEQvF5CpC=> M2fP[FI1KGh? NEe1UppqdmirYnn0d{BkdGmxcYXpco9tNWmwZIXj[YQheGixc4Doc5J6dGG2aX;uJI9nKHB3Mx?= NEPKVZUzOjZ{N{K5OC=>
A549 M2LOWmZ2dmO2aX;uJGF{e2G7 NYraOmFTOTEEoN88UeKh MUOxJIg> NYDiTlI6e3WycILld5NmeyCQYX7vMWNwNWmwZIXj[YQheDV|IHHjZ5VufWyjdHnvci=> NFPneIczOjV3OUOyNS=>
T47D  M3TrSWZ2dmO2aX;uJGF{e2G7 MlzMNlDDqG2P MmrRNlQhcA>? Mnv5SG1UVw>? M{S4VJBz\X[nboTzJGlTNWmwZIXj[YQh\GWpcnHkZZRqd25ib3[gTe67Ss7z MXGyNVE1PDhyNR?=
A29 MEF NUTncHB[TnWwY4Tpc44hSXO|YYm= Mk\rNVDDqM7:TdMg MUixbC=> MWDicI9kc3QEoITo[UBxcG:|cHjvdplt[XSrb36gc4YhSWu2IHH0JHNmejR5M9Mg NIn1fWczODB3M{e4NS=>
MDA-MB-453  NIDINW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{C4S|UuPDBizszN NVPoN3JwPzJiaB?= NWjLdIV6UUN3MDDv[kAyOCEQvF2= NVy5ZpNiOjByNUO3PFE>
PC-3 NGX3foZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVT2d4JNPS12MDFOwG0> MUe3NkBp NVT5c3RPUUN3MDDv[kAyOCEQvF2= M33ielIxODV|N{ix

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
p-AKT(Ser473) / p-AKT(Thr308); 

PubMed: 22739265     


Cells were serum-starved for 6 h and treated with KU-55933 (10 µmol/L) for 1 h before treatment with insulin (100 nmol/L) for 45 min. Cells were lysed, and cell lysates were subjected to SDS-PAGE and Western blotting for the detection of phospho-Akt at Se䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖

PARP / Cleaved PARP / Caspase-3 / Cleaved caspase-3 ; 

PubMed: 22739265     


ATM inhibition by KU-55933 induces apoptosis in differentiated but not undifferentiated SH-SY5Y cells. Cells were starved for 6 h in serum-free medium. KU-55933 (10 µmol/L) was added 1 h before insulin (100 nmol/L) treatment. After 3 h of insulin stimulat䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤

ATM-S1981 / ATM / p-p53(S15) / p53 ; 

PubMed: 20639198     


Antioxidant and ATM inhibitors blocked phosphorylation of ATM-S1981, Akt-S473, and p53-S15 as stimulated by H2O2 exposure. Cells were treated with 100 μm H2O2 for 30 min in the absence or presence of KU-55933. Whole cell lysates were subjected to Western 䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖

p21 / p27 / p53 ; 

PubMed: 20177072     


HMGE cells were incubated for the indicated times with 1 μm KU-55933 or DMSO. Total protein extracts were analyzed by Western blotting for p21WAF1/CIP1, p27KIP1, p53, or β-actin.

22739265 20639198 20177072
Immunofluorescence
p-S824 KAP1 / ZEBRA ; 

PubMed: 28249048     


HH514-16 cells were treated with NaB (upper panel) or NaB plus KU-55933 (1μM; middle panel) or NaB plus Torin1 (0.5μM; lower panel) for 24 hours and stained with anti-phospho KAP1 (S824) plus anti-ZEBRA antibodies and visualized at 1000X magnification.

28249048
体内試験 Suppression of ATM-dependent STAT3 activation by KU-55933 enhances TRAIL-mediated apoptosis through up-regulation of surface DR5 expression, whereas suppression of both STAT3 and NF-κB appeares to be involved in down-regulation of cFLIP accompanied by an additional increase in apoptotic levels. The ATM inhibitor KU-55933 affectes TRAIL-mediated apoptosis more strongly than the JAK2 inhibitor, AG490, or overexpression of STAT3β. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

- 合併

Purified enzyme assays:

ATM for use in the in vitro assay is obtained from HeLa nuclear extract by immunoprecipitation with rabbit polyclonal antiserum raised to the COOH-terminal 400 amino acids of ATM in buffer containing 25 mM HEPES (pH 7.4), 2 mM MgCl2, 250 mM KCl, 500 μM EDTA, 100 μM Na3VO4, 10% v/v glycerol, and 0.1% v/v Igepal. ATM-antibody complexes are isolated from nuclear extract by incubating with protein A-Sepharose beads for 1 hour and then through centrifugation to recover the beads. In the well of a 96-well plate, ATM-containing Sepharose beads are incubated with 1 μg of substrate glutathione S-transferase–p53N66 (NH2-terminal 66 amino acids of p53 fused to glutathione S-transferase) in ATM assay buffer [25 mM HEPES (pH 7.4), 75 mM NaCl, 3 mM MgCl2, 2 mM MnCl2, 50 μM Na3VO4, 500 μM DTT, and 5% v/v glycerol] at 37 °C in the presence or absence of inhibitor. After 10 minutes with gentle shaking, ATP is added to a final concentration of 50 μM and the reaction continued at 37 °C for an additional 1 hour. The plate is centrifuged at 250 × g for 10 minutes (4 °C) to remove the ATM-containing beads, and the supernatant is removed and transferred to a white opaque 96-well plate and incubated at room temperature for 1.5 hours to allow glutathione S-transferase-p53N66 binding. This plate is then washed with PBS, blotted dry, and analyzed by a standard ELISA technique with a phospho-serine 15 p53 antibody. The detection of phosphorylated glutathione S-transferase-p53N66 substrate is performed in combination with a goat antimouse horseradish peroxidase-conjugated secondary antibody. Enhanced chemiluminescence solution is used to produce a signal and chemiluminescent detection is carried out.
細胞試験:

[1]

- 合併
  • 細胞株: U2OS cells
  • 濃度: 10 μM
  • 反応時間: 2 hours
  • 実験の流れ:

    U2OS cells are exposed to ionizing radiation (3, 5, or 15 Gy) or UV (5 or 50 J/m2) and the ATM response determined by Western blot analysis of p53 serine 15 phosphorylation and stabilization of wild-type p53. Whole cell extracts are obtained from each time point, proteins separated by SDS-PAGE, and the ATM-specific increase in phosphorylated serine 15 measured with a p53 phospho-serine 15 specific antibody. Overall p53 stabilization with time is also observed with a p53-specific antibody (DO-1). Similarly, for studying ATM-dependent phosphorylations on H2AX, CHK1, NBS1, and SMC1, the following antibodies are used: CHK1 phospho-serine 345 and NBS1 phospho-serine 343 antibodies. Histone H2A (H-124) and CHK1 antibodies are also used, as well as SMC1 and SMC1 phospho-serine 966 antibodies. For determination of a cellular IC50 for KU-55933, the peak response time for p53 serine 15 phosphorylation of 2 hours is used to monitor inhibition of ATM. KU-55933 is titrated onto cells and preincubated for 1 hour before ionizing radiation. Using scanning densitometry, the percentage inhibition relative to vehicle control is calculated, and the IC50 value is calculated as for the in vitro determinations.


    (参考用のみ)
動物試験:

[3]

- 合併
  • 動物モデル: BALB/c nu/nu nude mice bearing LU1205 cells
  • 投薬量: 10 μM
  • 投与方法: --
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 33 mg/mL (83.44 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
混合させたのち直ちに使用することを推奨します。
3.95 mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 395.49
化学式

C21H17NO3S2

CAS No. 587871-26-9
Storage powder
in solvent
別名 N/A
Smiles O=C1C=C(OC(=C1)C2=CC=CC3=C2SC4=CC=CC=C4S3)N5CCOCC5

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

ATM/ATRシグナル伝達経路

ATM/ATR Inhibitors with Unique Features

相関ATM/ATR製品

Tags: KU-55933 (ATM Kinase Inhibitor)を買う | KU-55933 (ATM Kinase Inhibitor) ic50 | KU-55933 (ATM Kinase Inhibitor)供給者 | KU-55933 (ATM Kinase Inhibitor)を購入する | KU-55933 (ATM Kinase Inhibitor)費用 | KU-55933 (ATM Kinase Inhibitor)生産者 | オーダーKU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor)化学構造 | KU-55933 (ATM Kinase Inhibitor)分子量 | KU-55933 (ATM Kinase Inhibitor)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID